SCHEMBL14938244

SCHEMBL14938244

Cn1nccc1CCc1ncc(C(F)(F)F)cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.39
HDAC8 Q9BY41 3/20 0.39
HDAC6 Q9UBN7 3/20 0.39
KCNH2 Q12809 4/20 0.38
AGBL2 Q5U5Z8 1/20 0.36
CYP1A2 P05177 1/20 0.35
METAP2 P50579 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
KMT2A Q03164 2/20 0.33
PIK3CA P42336 1/20 0.33
MEN1 O00255 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
SCN2B O60939 1/20 0.33
SCN1B Q07699 1/20 0.33
SCN9A Q15858 1/20 0.33
P2RX7 Q99572 1/20 0.33
OXTR P30559 1/20 0.33
AVPR1A P37288 1/20 0.33
HDAC5 Q9UQL6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14937426 0.77 DAO (0.44) HDAC1HDAC8HDAC6CYP1A2METAP2
SCHEMBL14937805 0.75 AGBL2 (0.35) AGBL2KDM4EALDH1A1KMT2A
SCHEMBL13104691 0.74 AGBL2 (0.45) AGBL2KMT2AMEN1NPSR1POLQ
SCHEMBL14938123 0.73 TAAR1 (0.44) HDAC1HDAC8HDAC6OXTRAVPR1A
SCHEMBL14937826 0.71 TAAR1 (0.50) KDM4EALDH1A1GAAATM
SCHEMBL15805590 0.70 AGBL2 (0.47) AGBL2ALDH1A1KMT2AMEN1NPSR1
SCHEMBL14937792 0.69 DAO (0.44) HDAC1HDAC8HDAC6OXTRAVPR1A
SCHEMBL14938112 0.69 NOS1 (0.50) HDAC1HDAC8HDAC6KCNH2CYP1A2
SCHEMBL14938259 0.68 HDAC1 (0.49) HDAC1HDAC8HDAC6KMT2AOXTR
SCHEMBL10116242 0.67 AGBL2 (0.45) AGBL2KMT2AMEN1NPSR1POLQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642626-B2 Ethinyl-pyrazole derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-02-04 US disclosed
EP-2604602-A1 HETEROARYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-19 EP disclosed
EP-2599775-A1 ETHINYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-05 EP disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE GRIN2C, GRIN2B, GRIN3A HDAC1 239/4885HDAC8 1570/4885HDAC6 283/4885
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE GABRE, GRIN3A, GRIK5 HDAC1 867/4885HDAC8 2567/4885HDAC6 1304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.